Imidazoles

BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment of 2nd/3rd Line Non-Small Cell Lung Cancer (NSCLC) with EGFR Wild Type

Retrieved on: 
Wednesday, August 4, 2021
Organic chemistry, Chemistry, Carbonyl compounds, Carbamates, Taxanes, Diketopiperazines, Imidazoles, Plinabulin, Docetaxel

Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.

Key Points: 
  • Plinabulin is a first-in-class, selective immunomodulating microtubule-binding agent (SIMBA), which is a potent antigen presenting cell (APC) inducer.
  • The DUBLIN-3 Phase 3 trial is a randomized, single blind to patients, active controlled, global trial that enrolled 559 patients in 2nd and 3rd line NSCLC, EGFR wild type, with measurable lung lesion.
  • Plinabulin in combination with docetaxel (DP) showed statistically significant improvements compared to docetaxel alone (D) with topline data summarized below for ITT population (DP: n=278; D: n=281).
  • Now that checkpoint inhibitor immunotherapy has moved into first line, there is a vacuum in this indication, where treatment is heavily centered around docetaxel.

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Health, Chemical compounds, Breakthrough therapy, Amides, Chemotherapy, Imidazoles, Nirogacestat, Clinical trial

The Company expects to complete enrollment of the trial in the second half of 2021.

Key Points: 
  • The Company expects to complete enrollment of the trial in the second half of 2021.
  • In June 2021, SpringWorks entered into a collaboration to conduct a Phase 1/2 clinical trial evaluating mirdametinib in children and young adults with low-grade glioma.
  • SpringWorks also expects that two additional collaborator-sponsored trials will initiate enrollment in the second half of 2021, as previously disclosed: nirogacestat + Pfizers elranatamab and nirogacestat + Seagen's SEA-BCMA.
  • Net Loss Attributable to Common Stockholders: SpringWorks reported net loss of $47.0 million, or $0.97 per share, for the second quarter of 2021.

Kura Oncology to Report Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021
Life sciences, Health sciences, Drugs, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, Biopharmaceutical, P110α, Head and neck cancer

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021.

Key Points: 
  • SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the close of U.S. financial markets on Thursday, August 5, 2021.
  • ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update.
  • Kura Oncologyis a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer.
  • In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets, including patients who have HRAS and/or PIK3CA-dependent HNSCC.

Global Losartan Market (2020 to 2026) - by Source, Form, Strength, Distribution Channel, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Angiotensin II receptor antagonists, Chloroarenes, Imidazoles, Losartan, Tetrazoles, Angiotensin II receptor blocker, Marketplace, Financial market

The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.

Key Points: 
  • The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.
  • To estimate and forecast the market size of the Global Losartan Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global Losartan Market based on source, form, strength, distribution channel, application, end-user, company and regional distribution.
  • To identify key sustainable strategies adopted by market players in the Global Losartan Market.

Outlook on the Irritable Bowel Syndrome Treatment Global Market to 2028 - by Type, Product, Distribution Channel and Geography - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Health, General Health, Medical specialties, Clinical medicine, Gastroenterology, Abdominal pain, Irritable bowel syndrome, Lactams, Imidazoles, Lubiprostone, Rifaximin, Eluxadoline, Immuron, Small intestinal bacterial overgrowth

The factors such as increasing prevalence of irritable bowel syndrome (IBS) diseases and rising research & development activities drive the market growth.

Key Points: 
  • The factors such as increasing prevalence of irritable bowel syndrome (IBS) diseases and rising research & development activities drive the market growth.
  • However, the limited number of product availability and treatment inefficiency hinder the growth of the irritable bowel syndrome (IBS) treatment market.
  • The global irritable bowel syndrome (IBS) treatment market is segmented on the basis of type, product, and distribution channel.
  • The irritable bowel syndrome (IBS) treatment market, based on product, is segmented into rifaximin, eluxadoline, lubiprostone, linaclotide, and others.

14 - Alpha Demethylase Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Chemical compounds, Aromatic compounds, Organic compounds, Chloroarenes, Pipeline, Dioxolanes, Tertiary alcohols, Imidazoles, Orphan drugs

The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "14 - Alpha Demethylase Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "14-alpha demethylase inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in 14-alpha demethylase inhibitors pipeline landscape.
  • This segment of the report provides insights about the different 14-alpha demethylase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • 14-alpha demethylase inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Kura Oncology Announces Clinical Collaboration to Evaluate Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Retrieved on: 
Tuesday, July 6, 2021
Drugs, Health, Orphan drugs, Chloroarenes, Imidazoles, Tipifarnib, Farnesyltransferase inhibitor, Oncology, Head and neck cancer, Ras GTPase, Squamous cell carcinoma, HRAS

Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.

Key Points: 
  • Tipifarnib is Kuras farnesyl transferase inhibitor drug candidate currently in a registration-directed trial as a monotherapy in patients with HRAS mutant HNSCC.
  • Combining tipifarnib with alpelisib has the potential to provide a clinically meaningful increase in anti-tumor activity compared to when inhibiting either pathway alone, said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • We believe this clinical collaboration will enable us to potentially expand the use of tipifarnib to a significantly higher percentage of patients with advanced HNSCC.
  • Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide, accounting for more than 500,000 new cases each year.

BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin’s Development Program in Anti-cancer Indications

Retrieved on: 
Thursday, June 17, 2021
Diketopiperazines, Imidazoles, Chemistry, Plinabulin, Cancer

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the development program for its novel immune agent, Plinabulin, in anti-cancer indications on Friday, June 25th, at 8:00 a.m.

Key Points: 
  • NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the development program for its novel immune agent, Plinabulin, in anti-cancer indications on Friday, June 25th, at 8:00 a.m.
  • (Piedmont Cancer Institute), who will discuss the current treatment landscape and unmet medical need in treating patients with non-small cell lung cancer (NSCLC) and patients who failed checkpoint inhibitors.
  • Also featured will be a management discussion of BeyondSprings pipeline, including lead asset plinabulin, a selective immunomodulating microtubule-binding agent (SIMBA), being developed as a pipeline in a drug.
  • BeyondSprings first-in-class lead asset plinabulin, a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), is being developed a pipeline in a drug.

Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia

Retrieved on: 
Tuesday, May 25, 2021
Chemical compounds, Health sciences, Drugs, Imidazoles, Lactones, Pilocarpine, Microdosing

VISION-1 is the third Phase 3 study demonstrating the utility of the companys MAP technology in improving the therapeutic index of topical ophthalmic drugs.

Key Points: 
  • VISION-1 is the third Phase 3 study demonstrating the utility of the companys MAP technology in improving the therapeutic index of topical ophthalmic drugs.
  • In a post-study survey, 70% of study participants reported strong interest in using MicroLine for near vision improvement should it be approved.
  • Eyenovias MicroLine is a proprietary microdosed formulation of pilocarpine for presbyopia that is delivered via the Companys Optejet dispenser .
  • Eyenovia, Inc.(NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics.

BeyondSpring to Announce Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call on Friday, April 30, 2021

Retrieved on: 
Tuesday, April 27, 2021
Diketopiperazines, Imidazoles, Plinabulin, Cancer immunotherapy, Oncology, PD-L1, Medical specialties, Clinical medicine, Medicine

b'Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs.

Key Points: 
  • b'Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to improve clinical outcomes for patients who have high unmet medical needs.
  • BeyondSpring\xe2\x80\x99s first-in-class lead asset plinabulin, a Selective Immunomodulating Microtubule Binding Agent (SIMBA), is a \xe2\x80\x9cpipeline in a drug.\xe2\x80\x9d It has filed for NDA approval in the US and China for the prevention of chemotherapy-induced neutropenia (CIN) and has a fully enrolled pivotal study to test the anti-cancer benefit, with an overall survival primary endpoint, in non-small cell lung cancer (NSCLC).
  • Additionally, it is being broadly studied in combination with various immuno-oncology agents that could boost the effects of PD-1 / PD-L1 antibodies.
  • In addition to plinabulin, BeyondSpring\xe2\x80\x99s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation (TPD) drug discovery platform, which recently announced an R&D collaboration with Eli Lilly.\n'